Tempo Pharmaceuticals Garners $8,000,000 Series B Financing

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=95c37f3a-5181-4387-a0d7-ffb8d3044d6e&Preview=1
Date
1/3/2008
Company Name
Tempo Pharmaceuticals
Mailing Address
161 First Street Cambridge, MA 02142
Company Description
Tempo Pharmaceuticals is a private biopharmaceutical company focused on the development of novel, nanotechnology-based therapeutics in the areas of oncology, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Millennium Pharmaceuticals, Pfizer, Pharmacia, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.
Website
http://www.tempopharmaceuticals.com
Transaction Type
Venture Equity
Transaction Amount
$8,000,000
Transaction Round
Series B
Proceeds Purposes
Proceeds from the financing will be used to accelerate the development of Tempo’s preclinical pipeline of multi-compartmental, nanoparticle-based drugs that have the potential to substantially improve the efficacy and safety of existing and new therapeutics.
M&A Terms
Venture Investor
Polaris Venture Partners
Venture Investor
Venrock
Venture Investor
Bessemer Venture Partners
Venture Investor
Alexandria Real Estate Equities, Inc.